Main Story - Titan Pharmaceuticals - pgs. 1-23
Macro Market Commentary - pg. 24
News Briefs - pgs. 25-26
BSR Coverage Update - pgs. 27-30

Welcome to the debut issue of Biotech Monthly. In this issue we debut coverage on the diversified development-stage biotechnology company Titan Pharmaceuticals (TTP). With drugs addressing oncology and central nervous system disorders, the company has an attractive and deep pipeline. Their major problem is management does not seem willing to advance development of a drug unless they can find someone else to pay for it.

The following is an outline of this issue of Biotech Monthly.

Main Story - Titan Pharmaceuticals (AMEX:TTP)

Summary

Cash position
Table: Basic facts
Table: Product pipeline
Product pipeline
Business model
Investment case
Disclosure

Iloperidone

Table: Iloperidone indications and trials
Table: Worldwide antisychotic market
Traditional antipsychotics
Atypical antipsychotics
The Phase III studies
Table: Competitive landscape for atypical antipsychotics
A problem
New pivotal studies
Table: New iloperidone clinical trials
Iloperidon going forward

Spheramine

Table: Spheramine descriptions
Table: Parkinson's disease statistics
Table: Commercial Parkinson's treatment statistics
Cell implantation therapies
Table: Comparison of cell implantation therapies
Human fetal cells
Porcine fetal cells (Diacrin)
Human retinal pigment epithelial cells (Spheramine)
Concluding comments

Cancer products

Table: Potential amrket for Titan's products
Sidebar: Caveats for sizing potential markets
Cancer immunotherapy
Sidebar: Immune system components
Titan's cancer vaccines
Sidebar: Lung cancer defined
Competitive landscape
Table: Titan's competitive landscape
CeaVac
Table: CeaVac details
Table: Potential market indications
TriGem
Table: TriGem details
Small molecule cancer drugs
Pivanex
Gallium maltolate
Preclinical products
RB94
ProNeura
Summary
Table: Important investor milestones

What can go Wrong

Macro Market Commentary

News briefs

BSR Coverage Universe Updates